The stock of Vaxcyte Inc. (NASDAQ:PCVX) last traded at $44.18, up 0.02% from the previous session.
Data from the available sources indicates that Vaxcyte Inc. (NASDAQ:PCVX) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $70.00 and a low of $52.00, we find $64.00. Given the previous closing price of $44.17, this indicates a potential upside of 44.89 percent. PCVX stock price is now 35.46% away from the 50-day moving average and 69.67% away from the 200-day moving average. The market capitalization of the company currently stands at $3.43B.
In total, 0 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $62.20 as their price target over the next twelve months.
With the price target of $69, BTIG Research recently initiated with Buy rating for Vaxcyte Inc. (NASDAQ: PCVX)., while ‘Needham’ rates the stock as ‘Buy’.
In other news, Lukatch Heath, Director sold 4,335 shares of the company’s stock on Nov 10. The stock was sold for $199,989 at an average price of $46.13. Upon completion of the transaction, the Director now directly owns 3,125 shares in the company, valued at $0.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 26, VP, Research Fairman Jeff sold 10,000 shares of the business’s stock. A total of $400,000 was realized by selling the stock at an average price of $40.00. This leaves the insider owning 286,227 shares of the company worth $12.65 million. Insiders disposed of 339,133 shares of company stock worth roughly $14.98 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PCVX stock. A new stake in Vaxcyte Inc. shares was purchased by NATIONAL BANK OF CANADA /FI/ during the first quarter worth $39,123,000. AVIDITY PARTNERS MANAGEMENT LP invested $27,776,000 in shares of PCVX during the first quarter. In the first quarter, CAPITAL RESEARCH GLOBAL INVESTORS acquired a new stake in Vaxcyte Inc. valued at approximately $22,746,000. POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in PCVX for approximately $18,679,000. VIVO CAPITAL, LLC purchased a new stake in PCVX valued at around $17,871,000 in the second quarter. In total, there are 179 active investors with 74.10% ownership of the company’s stock.
With an opening price of $44.04 on Wednesday morning, Vaxcyte Inc. (NASDAQ: PCVX) set off the trading day. During the past 12 months, Vaxcyte Inc. has had a low of $16.78 and a high of $46.57. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 9.40, and a quick ratio of 9.40. The fifty day moving average price for PCVX is $32.61 and a two-hundred day moving average price translates $26.04 for the stock.
The latest earnings results from Vaxcyte Inc. (NASDAQ: PCVX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.8, missing analysts’ expectations of -$0.69 by -0.11. This compares to -$0.51 EPS in the same period last year. The company reported revenue of $58.58 million for the quarter, compared to $26.95 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 117.35 percent.
Vaxcyte Inc.(PCVX) Company Profile
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.